Join

Compare · MO vs ONCR

MO vs ONCR

Side-by-side comparison of Altria Group Inc. (MO) and Oncorus Inc. (ONCR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MO and ONCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • MO is the larger of the two at $119.50B, about 1451.4x ONCR ($82.3M).
  • MO has hit the wire 17 times in the past 4 weeks while ONCR has been quiet.
  • MO has more recent analyst coverage (19 ratings vs 0 for ONCR).
MetricMOONCR
Company
Altria Group Inc.
Oncorus Inc.
Price
$71.54+0.35%
$0.12-10.15%
Market cap
$119.50B
$82.3M
1M return
+5.03%
-
1Y return
+22.12%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
17
0
Recent ratings
19
0
MO

Altria Group Inc.

Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

ONCR

Oncorus Inc.

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest MO

Latest ONCR